PTC Therapeutics (PTCT) Misses Q4 EPS by 6c
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Join SI Premium – FREE
PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.85), $0.06 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $213 million versus the consensus estimate of $213.45 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- UBS Upgrades Stockland (SGP:AU) (STKAF) to Buy
- Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
